Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 3/20 | 0.47 |
| ▸ | TAS1R3 | Q7RTX0 | 2/20 | 0.45 |
| ▸ | TAS1R1 | Q7RTX1 | 2/20 | 0.45 |
| ▸ | TAS1R2 | Q8TE23 | 2/20 | 0.45 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.44 |
| ▸ | RAF1 | P04049 | 1/20 | 0.43 |
| ▸ | CNR2 | P34972 | 6/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.42 |
| ▸ | CNR1 | P21554 | 3/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206416 | 1.00 | RAB9A (0.47) | RAB9ANPC1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6205946 | 0.84 | RAB9A (0.51) | RAB9ANPC1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL6205950 | 0.84 | RAB9A (0.51) | RAB9ANPC1TAS1R3TAS1R1TAS1R2 | |
| SCHEMBL12544907 | 0.76 | MAPT (0.39) | CRHR1 | |
| SCHEMBL12544905 | 0.76 | MAPT (0.39) | CRHR1 | |
| SCHEMBL3714502 | 0.74 | DHODH (0.42) | RAF1 | |
| SCHEMBL5717596 | 0.73 | KDM4E (0.44) | RAF1 | |
| SCHEMBL6085342 | 0.70 | RAB9A (0.48) | RAB9ACRHR1 | |
| SCHEMBL6085337 | 0.70 | RAB9A (0.48) | RAB9ACRHR1 | |
| SCHEMBL6084047 | 0.70 | RAB9A (0.48) | RAB9ACRHR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1595871-A2 | Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases | NPS PHARMACEUTICALS, INC. (US) | 2005-11-16 | — | — | EP | disclosed |